- Все
- Corporate News
- Events & Exhibitions
FARMAMONDO new Website is now LIVE!
FarmaMondo is pleased to announce the launch of its brand new website! After months of hard work and dedication, we are delighted to officially announce …
Zion Medical appoints the FarmaMondo Group to support global named patient access to its novel therapy Gammora™
FarmaMondo and Zion Medical, an Israel startup pharma developer, signed today an agreement to establish a MAP for their novel drug Gammora. The product is …
FarmaMondo to exclusively manage access to Metreleptin (Myalept®) by Amryt Pharma for patients with lipodystrophy in CIS (excluding Russia).
Amryt Pharma (www.amrytpharma.com/) has appointed FarmaMondo, the world’s leader in paid-access to unlicensed medicines, to exclusively manage the access of its innovative therapy Metreleptin (FDA/EMA approval under …
EUSA and FarmaMondo Group establishes an Emergency Managed Access Program to allow Healthcare Providers to access Siltuximab (Sylvant©) for off label treatment of acute patients of COVID-19
While the world fights through COVID19 pandemic EUSA and Papa Giovani Hospital in Italy had initiated an observational study (SISCO trial — https://clinicaltrials.gov/ct2/show/NCT04322188?term=SISCO&draw=2&rank=1) on Siltuximab …
FarmaMondo to exclusively Manage Access to Lomitapide (Lojuxta®) for the Swiss and CIS markets.
Amryt Pharma (www.amrytpharma.com/) has appointed FarmaMondo, the world’s leader in paid-access to unlicensed medicines, to exclusively manage the access of its innovative therapy Lomitapide (EMA …
FarmaMondo to exclusively manage access of Qarziba® (Dinutuximab Beta) by EUSA Pharma for patients with High Risk Neuroblastoma in LATAM and APAC regions.
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines has been appointed by EUSA Pharma to extend its current exclusive distribution of Qarziba® …
FarmaMondo to manage access to Carmustine Obvius for the Italian market
FarmaMondo has been appointed to exclusively manage the access of Carmustine Obvius to Italian healthcare providers looking to fulfill unmet medical needs of patients with …
FarmaMondo upgrades its presence in Mexico by establishing a local legal entity
FarmaMondo SA announces it has established FarmaMondo Mexico, a fully owned subsidiary of FarmaMondo SA. The Mexican affiliate will upgrade the group’s capabilities in providing …
FarmaMondo Nordics receives GMP license from the Danish Medicines Agency
FarmaMondo Nordics Aps, a fully owned subsidiary of FarmaMondo SA, has received a GMP license from the Danish Medicines Agency. With this license in place, …
FarmaMondo to manage access to Asparaginase (Spectrila® by Medac Pharma) for patients with acute lymphoblastic leukemia in Russia and CIS region
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, will exclusively distribute Spectrila® via a Managed Access Program for targeted Healthcare Providers in …
Merck’s Keytruda tops chemotherapy for non-small cell lung cancer treatment
Merck’s Keytruda (Pembrolizumab) showed better results than chemotherapy at improving overall survival among first-line patients with non-small cell lung cancer in a trial whose results …
FDA extends use of Tagrisso to metastatic non-small-cell lung cancer
AstraZeneca’s Tagrisso has been approved by FDA as a first-line treatment for patients with metastatic non-small-cell lung cancer characterized by epidermal growth factor receptor (EGFR) …
FarmaMondo To Attend Upcoming Pharmagora Paris — 2018
FarmaMondo Team is pleased to inform you that is attending Pharmagora Paris 2018. PharmagoraPlus has been the single largest conference and exhibition in France dedicated to …
FarmaMondo appointed by Amomed Pharma to exclusively Manage Access for Argipressin (Empressin®) for Russia and CIS region
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Amomed Pharma to exclusively distribute Empressin® via a Managed Access …
FarmaMondo: Bringing Responsible Access Global
Read the full interview, appeared on the magazine Healthcare and Life Sciences Review with our CEO, Mr. Jaron Spigel, regarding the uniqueness of FarmaMondo business model. With two …
FarmaMondo establishes presence in south EU markets to provide direct to hospital service around supply of unlicensed medicines
FarmaMondo SA announces it has established operations through its Global Access business unit into several south EU markets to allow direct to hospital supply of …
FarmaMondo To Attend Upcoming Arab Health — 2018
FarmaMondo Team is pleased to inform you that also for 2018 is attending Arab Health in Dubai. Arab Health is the largest gathering of healthcare …
CIS Medical Workshop around high risk Neuroblastoma management
FarmaMondo has recently hosted two days of medical workshops in Saint Petersburg and Moscow on November 9th and 10th 2017, as part of its support for …
FarmaMondo establishes presence in Mexico to provide direct to hospital service around supply of unlicensed medicines
FarmaMondo SA announces it has established operations in Mexico to allow direct to hospital supply of unlicensed medicines, to cover spontaneous needs and our portfolio …
FarmaMondo to manage access to Dinutuximab beta EUSA for patients with Neuroblastoma
FarmaMondo to manage access to Qarziba® (Dinutuximab Beta) by EUSA Pharma) for patients with High Risk Neuroblastoma in Russia and CIS region
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by EUSA Pharma to exclusively distribute Qarziba® via a Managed Access …
FARMAMONDO Exhibits at Expopharm 2017 in Düsseldorf
Following the successful and great experience of last 2 years’ participation FarmaMondo will return again to exhibit at EXPOPHARM 2017which will be held in Düsseldorf, …
FarmaMondo to expand its operations in Russia and CIS
FarmaMondo is delighted to announce further expansion of its Russian operations. As of July 1st 2017 FarmaMondo Representative Office (Moscow, Russia) provides full service coverage …
FARMAMONDO Exhibits at Expopharm 2016 (Munich)
Following the successful experience of last year’s participation FarmaMondo will return to exhibit at EXPOPHARM 2016 which will be held in Munich, Germany from October …
FarmaMondo at Early Access Programmes Conference in London
FarmaMondo is proud to sponsor this unique event, Early Access Programmes Conference, held in London , UK, on 29th — 30 th November 2016. The …
FarmaMondo appointed by Ideogen Pharma to Manage Access for Carmustine (Bicnu®) for Swiss market
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Ideogen Pharma to exclusively distribute Bicnu® (Emcure) via a Managed …
Farmamondo and AOP signs exclusive partnership for Russia
Farmamondo and AOP Orphan signs an exclusive registration, marketing and distribution agreement for AOP’s novel therapy Tetrabenazine indicated for Huntington disease. The agreement covers the …
Farmamondo approves Normokineztine in Russia!
FarmaMondo approves Normokineztine in Russian Federation for Huntington disease patients. The product, license to FarmaMondo from AOP Orphan, has been approved as the sole indicated …
FarmaMondo approves Ellanse in Taiwan
FarmaMondo announces the approval of Ellanse, an innovative product in the esthetic segment, by the Taiwan local regulatory body – TFDA – as a medical …
FarmaMondo appointed by Rev Pharma to exclusively Manage Access for Curefini® outside the United States
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed to exclusively distribute Curefini® dermal ointment via a Managed Access Program …
FARMAMONDO honored as “Top trustworthy Swiss companies” by Dun & Bradstreet
FarmaMondo is proud to announce that has been honored as «One of the Top trustworthy Swiss companies” by Dun & Bradstreet, a considerable business information …
FarmaMondo re-position its Swiss retail unit to adapt to Group strategy
FarmaMondo completes a rebranding campaign for its Swiss local retail unit. The Swiss retail unit, known to be the corner stone of the FarmaMondo historical …
FarmaMondo establishes presence in Argentina to provide direct to hospital service around supply of unlicensed medicines
FarmaMondo SA announces it has established operations in Argentina to allow direct to hospital supply of unlicensed medicines, to cover spontaneous needs and in support …
FarmaMondo appointed by Orion Pharma to Manage Access for levosimendan IV (Simdax®) for Swiss market
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Orion Pharma to distribute Simdax® via a Managed Access Program …
FarmaMondo establishes Its Brazilian subsidiary
FarmaMondo announces the establishment of its Brazilian subsidiary in Sao Paolo, Brazil. The subsidiary will facilitate the company’s vision and strategies in the Brazilian market …
FarmaMondo appointed by Adienne to Manage Access for Thiotepa (Tepadina®)
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by ADIENNE to distribute Tepadina® via a Managed Access Program for …
FarmaMondo establish presence in China
FarmaMondo SA announces it has established operations in Beijing, China. The Chinese affiliate will upgrade the FarmaMondo group capabilities in providing paid access to unlicensed …